Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Renuka V. Iyer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3643-8621; OpenAlex author ID A5055725897. Sources: ClinicalTrials.gov.

Their work

Papers
9 (first author 1, last author 2)
Trials
6 (principal investigator on 6)
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2004: 1 trial · 2005: none · 2006: none · 2007: 2 trials · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 1 paper, 1 trial · 2013: 1 paper · 2014: 3 papers · 2015: 1 trial · 2016: none · 2017: 1 paper · 2018: none · 2019: 2 papers, 1 trial · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 9

  1. Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma. Co-author DOI 10.1016/j.esmogo.2025.100194↗
  2. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Co-author DOI 10.1097/coc.0000000000000492↗
  3. Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. First author DOI 10.3390/cancers11121980↗
  4. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Last author DOI 10.1007/s00280-017-3375-9↗
  5. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective tria… Co-author DOI 10.1002/cncr.28648↗
  6. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-con… Co-author DOI 10.1097/mpa.0000000000000095↗
  7. Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicente… Last author DOI 10.3978/j.issn.2078-6891.2014.070↗
  8. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. Co-author DOI 10.3978/j.issn.2078-6891.2013.045↗
  9. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. Co-author DOI 10.3978/j.issn.2078-6891.2012.029↗

Trials 6

  1. Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, … Principal investigator NCT03736720↗
  2. Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer Principal investigator NCT02227940↗
  3. Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Can… Principal investigator NCT01497392↗
  4. Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer Principal investigator NCT00470535↗
  5. Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery Principal investigator NCT00524069↗
  6. Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer Principal investigator NCT00100815↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christos K Fountzilas · 3 shared papers, 2017–2025 · strength 0.45
  2. Alok A. Khorana · 1 shared paper, 2025 · strength 0.23
  3. Deepak Vadehra · 1 shared paper, 2025 · strength 0.23
  4. Thejus Jayakrishnan · 1 shared paper, 2025 · strength 0.23
  5. Wen Wee Ma · 3 shared papers, 2012–2019 · strength 0.17
  6. Medhavi Gupta · 1 shared paper, 2019 · strength 0.16
  7. Milind M. Javle · 2 shared papers, 2014 · strength 0.09
  8. Alex A. Adjei · 1 shared paper, 2019 · strength 0.08
  9. Hao Xie · 1 shared paper, 2019 · strength 0.08
  10. Robert M. Straubinger · 1 shared paper, 2019 · strength 0.08
  11. Andrew H. Ko · 2 shared papers, 2014 · strength 0.08
  12. Katherine Van Loon · 2 shared papers, 2014 · strength 0.08
  13. Tanios Bekaii‐Saab · 2 shared papers, 2014 · strength 0.08
  14. David R. Fogelman · 2 shared papers, 2014 · strength 0.08
  15. Kilian Salerno May · 2 shared papers, 2012–2013 · strength 0.06
  16. Gary Yang · 2 shared papers, 2012–2013 · strength 0.06
  17. Nadia Karen Malik · 2 shared papers, 2012–2013 · strength 0.06
  18. Boris W. Kuvshinoff · 2 shared papers, 2012–2013 · strength 0.06
  19. Sidra Anwar · 1 shared paper, 2014 · strength 0.05
  20. Mark M. Zalupski · 1 shared paper, 2014 · strength 0.04
  21. Shubham Pant · 1 shared paper, 2014 · strength 0.04
  22. Robert A. Wolff · 1 shared paper, 2014 · strength 0.04
  23. George P. Kim · 1 shared paper, 2014 · strength 0.04
  24. Margaret A. Tempero · 1 shared paper, 2014 · strength 0.04
  25. Vincent J. Picozzi · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.